methyl 4-[6-(cyclopentyloxycarbonyl)aminoindazol-1-ylmethyl]-3-methoxybenzoate | 104436-84-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 4-[6-(cyclopentyloxycarbonyl)aminoindazol-1-ylmethyl]-3-methoxybenzoate
• 英文别名: methyl 4-[[6-(cyclopentyloxycarbonylamino)indazol-1-yl]methyl]-3-methoxybenzoate
• CAS: 104436-84-2
• 化学式: C₂₃H₂₅N₃O₅
• 分子量: 423.469
• InChiKey: TUJBRKRDMAJSLT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  91.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 4-[6-(cyclopentyloxycarbonyl)aminoindazol-1-ylmethyl]-3-methoxybenzoate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 30.0h， 生成 4-[6-(环戊氧基羰基)-氨基吲唑-1-基甲基]-3-甲氧基苯甲酸
  参考文献：
  名称：

  Evolution of a series of peptidoleukotriene antagonists: synthesis and structure-activity relationships of 1,6-disubstituted indoles and indazoles

  摘要：

  A perception of structural similarities between two independent series of leukotriene antagonists (one emanating from FPL 55712 and one based upon the leukotrienes themselves) led to the discovery of a novel class of indole and indazole derived antagonists of peptidoleukotrienes. A systematic exploration of C-6 substituted 4-(indol-1-ylmethyl)-3-methoxybenzoic acids identified cyclopentylacetamide and cyclopentylurethane as preferred substituents. The corresponding indazoles were equipotent. These compounds are selective leukotriene antagonists with pKB values of 7.5-7.8 vs LTE4 on guinea pig trachea.

  DOI：

  10.1021/jm00168a036
• 作为产物：
  描述：

  4-溴甲基-3-甲氧基苯甲酸甲酯 在 palladium on activated charcoal 氢气 、 溶剂黄146 、 乙酸乙酯 、 三乙胺 作用下， 以 二氯甲烷 、 乙酸乙酯 、 丙酮 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 102.25h， 生成 methyl 4-[6-(cyclopentyloxycarbonyl)aminoindazol-1-ylmethyl]-3-methoxybenzoate
  参考文献：
  名称：

  Evolution of a series of peptidoleukotriene antagonists: synthesis and structure-activity relationships of 1,6-disubstituted indoles and indazoles

  摘要：

  A perception of structural similarities between two independent series of leukotriene antagonists (one emanating from FPL 55712 and one based upon the leukotrienes themselves) led to the discovery of a novel class of indole and indazole derived antagonists of peptidoleukotrienes. A systematic exploration of C-6 substituted 4-(indol-1-ylmethyl)-3-methoxybenzoic acids identified cyclopentylacetamide and cyclopentylurethane as preferred substituents. The corresponding indazoles were equipotent. These compounds are selective leukotriene antagonists with pKB values of 7.5-7.8 vs LTE4 on guinea pig trachea.

  DOI：

  10.1021/jm00168a036

文献信息

• Indole and indazole keto sulphones as leukotriene antagonists
  申请人：ICI Americas Inc.

  公开号：US04837235A1

  公开（公告）日：1989-06-06

  This invention provides a series of novel keto sulfones of formula I ##STR1## in which the group .dbd.A-- is selected from .dbd.C(Ra)-- and .dbd.N-- and the other radicals have the meanings defined in the following specification. The compounds of formula I are leukotriene antagonists. The invention also provides pharmaceutically acceptable salts of the formula I compounds; pharmaceutical compositions containing the formula I compound, or their salts, for use in the treatment of, for example, allergic or inflammatory diseases, or endotoxic or traumatic shock conditions; and processes for the manufacture of the formula I compounds, as well as intermediates for use in such manufacture.

  这项发明提供了一系列新颖的化合物，其化学式为I ##STR1## 其中，基团 .dbd.A-- 从 .dbd.C(Ra)-- 和 .dbd.N-- 中选择，其他基团的含义在下文规定。化合物I是白三烯拮抗剂。该发明还提供了化合物I的药学上可接受的盐；含有化合物I或其盐的药物组合物，用于治疗过敏性或炎症性疾病，或内毒素性或创伤性休克等疾病；以及用于制造化合物I的工艺，以及用于制造中间体的工艺。
• Heterocyclic amides
  申请人：ICI AMERICAS INC.

  公开号：EP0179619B1

  公开（公告）日：1990-09-05
• Medicinal indole and indazole keto sulphone derivatives
  申请人：ZENECA INC.

  公开号：EP0227241B1

  公开（公告）日：1996-09-11
• US4837235A
  申请人：——

  公开号：US4837235A

  公开（公告）日：1989-06-06
• US4997844A
  申请人：——

  公开号：US4997844A

  公开（公告）日：1991-03-05